Brief: Cadrenal Therapeutics Announces Collaboration Agreement With Abbott
04/03/2025 13:14
March 4 (Reuters) - Cadrenal Therapeutics Inc CVKD.O: CADRENAL THERAPEUTICS ANNOUNCES COLLABORATION AGREEMENT WITH ABBOTT IN SUPPORT OF PIVOTAL STUDY OF TECARFARIN IN PATIENTS WITH HEARTMATE 3™ LVAD CADRENAL THERAPEUTICS INC - ABBOTT TO SHARE INSIGHTS FROM HEARTMATE 3 TRIALS Source text: ID:nBw3JJBwra Further company coverage: CVKD.O (Reuters.Briefs@thomsonreuters.com)
Recent news on Cadrenal Therapeutics
See all newsCadrenal Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Cadrenal Therapeutics Q2 net loss narrows as operating expenses fall
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology